{{Rsnum
|rsid=568157
|Chromosome=11
|Orientation=plus
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene=LOC101054525
|position=101153551
|Gene_s=LOC101054525
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 22.1 | 55.8 | 22.1
| HCB | 95.6 | 4.4 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 60.0 | 35.2 | 4.8
| ASW | 57.9 | 38.6 | 3.5
| CHB | 95.6 | 4.4 | 0.0
| CHD | 97.2 | 2.8 | 0.0
| GIH | 54.5 | 35.6 | 9.9
| LWK | 61.8 | 33.6 | 4.5
| MEX | 39.7 | 46.6 | 13.8
| MKK | 66.0 | 30.1 | 3.8
| TSI | 37.3 | 44.1 | 18.6
| HapMapRevision=28
}}Part of a haplotype [[Gs286]], standalone effect for [[endometrial cancer]] is ambiguous.

No statistically significant interaction with 17-alpha-hydroxyprogesterone caproate for reducing recurrent preterm birth detected. {{PMID|21600550|OA=1
}}

{{PMID Auto GWAS
|PMID=20547493
|Trait=Endometrial cancer
|Title=Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach.
|RiskAllele=G
|Pval=0.47
|OR=0.95
|ORtxt=[0.82-1.11]
|OA=1
}}

{{PMID|21600550|OA=1
}} Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate

{{PMID|15632380}} Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}